« Return to News | Awards & Advancement

Armada names EVP of industry relations & advocacy

Monday, June 3, 2013 04:10 PM

Armada Health Care, a group purchasing and channel management organization for the specialty pharmacy market, has appointed Mike Baldzicki—EVP of industry relations & advocacy.

Baldzicki will implement strategic business development to cultivate opportunities to speak and present on pertinent industry topics that affect Armada and its client base at industry events within key market sectors for specialty pharmacy.

With 14 years of pharmaceutical and biotech industry experience, including roles in national and regional managed markets, specialty supply channels, sales management and specialty brand management, Baldzicki offers insight into specialty pharmacy trends, distribution, contracting, reimbursement and the application of health outcomes and economic evidence to prove value proposition. 

Baldzicki is active in the biotech community and is a member of the Academy of Managed Care Pharmacy, Specialty Pharmacy Association of America, Pharmaceutical Care Management Association, Immune Deficiency Foundation Committee and Strathmore's Who's Who for Healthcare Professionals.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.